The Global Tribune

Peripheral T-Cell Lymphoma (PTCL) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Peripheral T-Cell Lymphoma (PTCL) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

March 16
11:54 2020
Peripheral T-Cell Lymphoma (PTCL)  Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Peripheral T-Cell Lymphoma (PTCL) – Market Insights, Epidemiology, and Market Forecast-2030

Albany, US – DelveInsight has launched a new report on Peripheral T-Cell Lymphoma Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Peripheral T-Cell Lymphoma (PTCL) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Peripheral T-Cell Lymphoma (PTCL), historical and forecasted epidemiology as well as the Peripheral T-Cell Lymphoma (PTCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. The estimates suggest higher incidence of PTCL in the United States with 7,368 cases in 2017.
  2. Market Size of PTCL in the US was found to be USD 616 Million in 2017.
  3. Peripheral T Cell Lymphoma accounts for approx. about 10% of all Non-Hodgkin’s Lymphoma (NHL) cases.
  4. PTCLs typically affect middle aged to elderly patients.

 

Key benefits of the Report

1. Peripheral T-Cell Lymphoma market report covers a descriptive overview and comprehensive insight of the Peripheral T-Cell Lymphoma epidemiology and Peripheral T-Cell Lymphoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Peripheral T-Cell Lymphoma market report provides insights on the current and emerging therapies. 

3. Peripheral T-Cell Lymphoma market report offers a global historical and forecasted market covering drug outreach in 7MM.

4. Peripheral T-Cell Lymphoma market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Peripheral T-Cell Lymphoma market.

Request for Sample Pages:  https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

“According to DelveInsight, PTCL cases in United States demonstrates that most of the patients at the time of diagnosis are in the later stages (III-IV).”

 

 

 

The peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group of diseases representing approximately ∼10% to 15% of non-Hodgkin lymphomas. It usually develops from mature-stage white blood cells called T-cells and natural killer (NK) cells.

Most PTCL subtypes are aggressive (fast-growing) lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell/T-cell lymphoma.

The exact cause of Peripheral T-cell Lymphoma is unknown, it can be associated with the exposure to Epstein-Barr virus (EBV) or to the human T-cell leukaemia virus-1 (HTLV-1).

The Peripheral T-cell Lymphoma was classified by WHO in 2008 and updated in 2016.

According to this, the Peripheral T-cell Lymphomas can be broadly classified according to the site of origin of the malignant T cell in the body- Nodal, Extranodal, Cutaneous and Leukemic.

With no standard drug treatments available in clinical practice, the response rate of the cancer to conventional chemotherapies is low, the tolerance is poor, relapse often occurs.

Increasing healthcare expenditure, rise in R&D activities, and awareness among patients about the treatment options will support the market growth for PTCL

 

 “As per DelveInsight’s Analysis, Spain had the lowest incident population of 771 cases in 2017 among EU5 countries.”

Some of the key companies working on Peripheral T-Cell Lymphoma are:

  • Solasia Pharma
  • Aileron Therapeutics
  • HUYA Bioscience
  • Eisai

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Peripheral T-Cell Lymphoma treatment scenario in the upcoming years:-

 Drugs Covered:

  • Darinaparsin
  • ALRN 6924
  • HBI-8000
  • E7777

And Many Others.

Request a Free Sample Report @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

 Table of Contents:

1. Key Insights

2. Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance

2.1. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2017

2.2. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2030

3. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)

3.1. Introduction

3.2. Classification of Peripheral T-cell Lymphoma

3.2.1. WHO Classification System

3.3. Subtypes of Peripheral T cell lymphoma

3.4. Signs and Symptoms

3.5. Cause of Peripheral T-cell Lymphoma

3.6. Pathophysiology

3.7. Staging

3.8. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

5. G8 Total Incident Population of PTCL

6. Country Wise-Epidemiology of PTCL

6.1. United States

6.1.1. Diagnosed Incident Cases of PTCL in United States

6.1.2. Stage Wise Incidence of PTCL Cases in United States

6.1.3. Type Specific Incidence of PTCL in United States

6.2. EU5

6.3. Germany

6.3.1. Diagnosed Incident Cases of PTCL in Germany

6.3.2. Stage Wise Incidence of PTCL Cases in Germany

6.3.3. Type Specific Incidence of PTCL Cases in Germany

6.4. Italy

6.4.1. Diagnosed Incident Cases of PTCL in Italy

6.4.2. Stage Wise Incidence of PTCL in Italy

6.4.3. Type Specific Incidence of PTCL in Italy

6.5. Spain

6.5.1. Diagnosed Incident Cases of PTCL in Spain

6.5.2. Stage Wise Incidence of PTCL Cases in Spain

6.5.3. Type Specific Incidence of PTCL Cases in Spain

6.6. France

6.6.1. Diagnosed incident cases of PTCL in France

6.6.2. Stage Wise Incidence PTCL Cases in France

6.6.3. Type Specific Incidence of PTCL Cases in France

6.7. United Kingdom

6.7.1. Diagnosed Incident Cases of PTCL in United Kingdom

6.7.2. Stage Wise PTCL Cases in United Kingdom

6.7.3. Type Specific Incidence of PTCL Cases in United Kingdom

6.8. Japan

6.7.1. Assumption and Rationale

6.7.2. Diagnosed Incident Cases of PTCL in Japan

6.7.3. Stage Wise PTCL Cases in Japan

6.7.4. Type Specific Incidence of PTCL Cases in Japan

6.9. China

6.7.1. Assumption and Rationale

6.7.2. Diagnosed Incident Cases of PTCL in China

6.7.3. Stage Wise PTCL Cases in China

6.7.4. Type Specific Incidence of PTCL Cases in China

7. Treatment Practices

7.1. Treatment Goals

7.1.1. Treatment for Newly Diagnosed Patients

7.1.2. Treatment for Patients with Relapsed or Refractory PTCL

7.2. Treatment Options

8. Treatment Algorithm

8.1. United States

8.1.1. Nation Comprehensive Cancer Network (NCCN)

8.2. Europe

8.2.1. ESMO Guidelines

8.2.2. Integrated Management Algorithm

9. Unmet Needs

10. Key Cross Competition: Marketed Drugs

10.1. Beleodaq (Belinostat): Onxeo S.A.

10.1.1. Drug Description

10.1.2. Mechanism of Action

10.1.3. Advantages & Disadvantages

10.1.4. Safety and Efficacy of Beleodaq

10.1.5. Product Profile

10.2. Istodax (Romidepsin): Celgene Corporation

10.2.1. Drug Description

10.2.2. Mechanism of Action

10.2.3. Advantages & Disadvantages

10.2.4. Safety and Efficacy of Istodax

10.2.5. Product Profile

10.3. Folotyn (Pralatrexate): Spectrum Pharmaceuticals

10.3.1. Drug Description

10.3.2. Mechanism of Action

10.3.3. Advantages & Disadvantages

10.3.4. Safety and Efficacy of Folotyn

10.3.5. Product Profile

10.4. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.

10.4.1. Drug Description

10.4.2. Mechanism of Action

10.4.3. Advantages & Disadvantages

10.4.4. Safety and Efficacy of Poteligeo

10.4.5. Product Profile

10.5. Adcetris (Brentuximab vedotin): Seattle Genetics

10.5.1. Drug Description

10.5.2. Mechanism of Action

10.5.3. Regulatory Milestones

10.5.4. Advantages & Disadvantages

10.5.5. Safety and Efficacy of Adcetris

10.5.6. Product Profile

To be continued in the report…

11. Emerging Drugs Analysis

11.1. Key cross competition- Emerging Therapies

11.2. Denileukin diftitox: Eisai

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Product Profile

11.3. Darinaparsin: Solasia Pharma

11.3.1. Product Description

11.3.2. Other Developmental Activities

11.3.3. Clinical Development

11.3.4. Product Profile

11.4. IPH4102: Innate Pharmaceuticals

11.4.1. Product Description

11.4.2. Other Developmental Activities

11.4.3. Clinical Development

11.4.4. Product Profile

12 Other Promising Candidates

12.1 Masitinib: AB Science

12.1.1 Product Description

12.1.2 Clinical Development

12.1.3 Safety and Efficacy

12.1.4 Product Profile

12.2 Fenretinide: CerRx

12.2.1 Product Description

12.2.2 Other Developmental Activities

12.2.3 Clinical Development

12.2.4 Safety and Efficacy

12.2.5 Product Profile

12.3 Ruxolitinib: Incyte

12.3.1 Product Description

12.3.2 Other Developmental Activities

12.3.3 Clinical Development

12.3.4 Safety and Efficacy

12.3.5 Product Profile

12.4 Tipifarnib: Kura Oncology

12.4.1 Other Developmental Activities

12.4.2 Clinical Development

12.4.3 Safety and Efficacy

12.4.4 Product Description

12.4.5 Product Profile

12.5 Plitidepsin: PharmaMar

12.5.1 Product Description

12.5.2 Other Developmental Activities

12.5.3 Clinical Development

12.5.4 Product Profile

13 Peripheral T-cell Lymphoma (PTCL): G8 Countries Market Analysis

13.1 Key Findings

13.2 Total Market Size of Peripheral T-cell Lymphoma (PTCL) in G8 Countries

13.3 G8: Market Outlook

14 The United States: Market Outlook

14.1 United States Market Size

14.1.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

14.1.2 Market Size of PTCL by Therapies in US

15 EU-5 Countries: Market Outlook

15.1 Germany

15.1.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

15.1.2 Market Size of PTCL by Therapies in Germany

15.2 France

15.2.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

15.2.2 Market Size of PTCL by Therapies in France

15.3 Italy

15.3.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

15.3.2 Market Size of PTCL by Therapies in Italy

15.4 Spain

15.4.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

15.4.2 Market Size of PTCL by Therapies in Spain

15.5 United Kingdom

15.5.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

15.5.2 Market Size of PTCL by Therapies in UK

16 Japan: Market Outlook

16.1 Japan: Market Size

16.1.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

16.1.2 Market Size of PTCL by Therapies in Japan

17 China: Market Outlook

17.1 China: Market Size

17.1.1 Total Market size of Peripheral T-cell Lymphoma (PTCL)

17.1.2 Market Size of PTCL by Therapies in China

18 Market Drivers

19 Market Barriers

20 Appendix

21 Report Methodology

21.1 Sources Used

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Related Reports:

Peripheral T-Cell Lymphoma – Pipeline Insights, 2020

The Peripheral T-Cell Lymphoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peripheral T-Cell Lymphoma across the complete product development cycle, including all clinical and nonclinical stages.

Peripheral T-Cell Lymphoma – Epidemiology Forecast to 2030

The Peripheral T-Cell Lymphoma epidemiology covered in the report provides historical as well as forecasted Peripheral T-Cell Lymphoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/